ARPA-H Presentation at the Non-Dilutive Funding Summit
The 21st Non-Dilutive Funding Summit brought together hundreds of life science industry leaders with representatives from some of the leading funding agencies including ARPA-H, BARDA, CPRIT, CIRM, Breakthrough T1D and more, giving attendees the opportunity to learn more in-depth about what non-dilutive funding opportunities are available and relevant for their R&D directly from the funding agencies.
Additionally, the 2025 FreeMind Elite honorees took to the stage to present about their companies research and pipelines and their journey to securing non-dilutive funding.
This free summit is hosted by the FreeMind Group. FreeMind helps companies secure non-dilutive funding for life science R&D and wins over $100 million each year for clients. Follow us on LinkedIn or get our newsletter for news about non-dilutive funding opportunities, announcements about conferences with the best partnering, and discounts for those conferences.
ARPA-H
ARPA-H advances high-potential, high-impact biomedical and health research that cannot be readily accomplished through traditional research or commercial activity. ARPA-H awardees are developing entirely new ways to tackle the hardest challenges in health.
Dr. Andy Kilianski
Dr. Andy Kilianski joined ARPA-H in May 2023 from the International AIDS Vaccine Initiative (IAVI), where he served as senior director for emerging infectious diseases. During this time, he led IAVI’s filovirus vaccine portfolio – including vaccines focused on Marburg virus and Sudan virus – while also supporting strategy development and key stakeholder engagement across the entire emerging infectious diseases portfolio.
Before joining IAVI, Kilianski was a senior scientist and Science and Technology manager at the Department of Defense, where he built programs focused on countering emerging biological threats. During the onset of the COVID-19 pandemic, Kilianski led interdisciplinary teams on the Department of Defense COVID-19 Task Force, which focused on vaccine development, supply chain resilience, and COVID-19 operational data tracking and management. Kilianski received his doctorate in microbiology and immunology from Loyola University of Chicago, where he studied virus-host interactions important for coronavirus pathogenesis.
